Price movement over the last 24 hours
Adecoagro SA vs Illumina, Inc. — how do they compare? Adecoagro SA trades at $10.17 (market cap $1.39B), while Illumina, Inc. trades at $186.84 (market cap $29.01B). The key difference: Illumina, Inc. is far larger — about 20.9× Adecoagro SA's market cap, and Adecoagro SA pays a 3.08% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| AGRO | ILMN | |
|---|---|---|
Market Cap | $1.39B | $29.01B |
Sector | Technology | Health |
52-Week High | $15.25 | $194.33 |
52-Week Low | $7.13 | $91.00 |
Enterprise Value | $3.42B | $30.40B |
Dividend Yield | 3.08% | — |
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.48, down 1.66% today, with a bearish technical signal despite neutral oscillators. The company reported mixed quarterly results, missing Q1 2026 EPS estimates but showing strong adjusted EBITDA growth. Valuation metrics appear attractive with P/S of 0.71 and P/B of 0.78, though profitability remains weak with a 0.91% net margin. Recent news highlights innovation in agriculture operations and a declared $0.12 dividend for H1 2026.
The stock offers value appeal with below-market multiples and analyst consensus target of $12.75 implying 34% upside. However, inconsistent earnings performance and negative net income in 2025 pose execution risks. The bearish technical trend and competitive pressures in sustainable agriculture require careful monitoring for potential investors.
ILMN trades at $191.76, up 1.63% with bullish technical momentum and strong earnings beats. The stock shows robust profitability with 66.2% gross margins and 19.42% net income margins, though valuations remain elevated with a P/E of 34.31. Recent product launches like StrataMap Spatial and NovaSeq X demand drive growth, while Roche's new Axelios sequencer introduces competitive pressure. Cash flow improved to $291M in 2025 after prior volatility.
Outlook remains positive with analyst consensus at Buy (51%) and a $168.89 price target, though current price exceeds consensus. Key risks include rising debt-to-asset ratios (29.93% in 2025) and China market challenges. Upside depends on execution against new competition and sustaining high-margin sequencing growth.
Trailing returns across standard periods
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →